Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Podcasts|November 4, 2019
Atypical Antipsychotics in Bipolar Depression
Author(s)Chris Aiken, MD
We have nearly a dozen atypical antipsychotics to choose from, but do all of these work in bipolar disorder and which of them should we start with? Listen to the podcast.
Advertisement
We have nearly a dozen atypical antipsychotics to choose from, but do all of these work in bipolar disorder and which of them should we start with? Listen to the podcast.
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psychiatric Pipeline in Review: Quarter 3, 2026
2
VA Expands Informed Consent Requirements for Psychotropic Medications Starting in 2027
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
September 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5